Benefits
Indigestion and stomach comfort after meals
Two placebo-controlled trials in adults with functional dyspepsia, each of a different blend, reported better indigestion scores. In a maker-run trial of 40 adults, DigeZyme 50 mg three times daily for 60 days improved all five symptom scales more than placebo. A separate fungal blend, 400 mg a day for 2 months, improved dyspepsia quality of life, pain and sleep scores in 120 adults. Heartburn fell only within the DigeZyme group.
Choosing a blend or a single enzyme
A broad blend is a general option for discomfort after mixed meals, and it is the form tested in the two dyspepsia trials. When one food is the clear trigger, a single matched enzyme is a simpler choice: lactase for dairy, alpha-galactosidase for beans, fructan hydrolase for fructan-rich foods, each with its own page and evidence. Pancrelipase is a prescription product for diagnosed low pancreatic enzyme output, not a supplement.
Starch, protein and fat digestion
DigeZyme combines five enzymes that act on starch (alpha-amylase), protein (protease), fat (lipase), plant fiber (cellulase) and milk sugar (lactase). This describes what each enzyme does in the gut. No published trial has measured how much more of a meal is digested or absorbed with the blend, so effects on nutrient uptake are unproven.
Post-exercise muscle soreness
One small 3-day trial run with the maker gave 20 healthy men DigeZyme 50 mg three times daily or placebo after eccentric exercise. Thigh pressure-pain and McGill pain questionnaire scores favored the enzyme group, but calf pressure-pain, muscle power, grip strength and the muscle damage markers creatine kinase and LDH did not differ significantly. It appeared in a journal not indexed in PubMed and has not been repeated.
Lactose digestion
The lactase in DigeZyme splits lactose into glucose and galactose, the same job a stand-alone lactase supplement does. Neither dyspepsia trial measured lactose digestion or dairy tolerance, and a blend may supply less lactase than a dedicated product, so this describes how the enzyme works rather than a tested effect of the blend.
Mechanism of action
Enzyme survival through the stomach
DigeZyme's enzymes are made by fermentation with fungi and one bacterium. The maker's trial paper argues that food buffers stomach acid and that microbial enzymes may survive, or regain activity, once they reach the small intestine, but it presents this as a hypothesis drawn from other studies. No measured pH-stability data for the blend have been published.
Substrate-specific hydrolytic activity
Each enzyme component targets its own substrate: alpha-amylase cleaves alpha-1,4-glycosidic bonds in starch, protease cleaves peptide bonds, lipase hydrolyzes ester bonds in triglycerides, cellulase cleaves beta-1,4-glycosidic bonds in cellulose, and lactase cleaves beta-galactosidic bonds in lactose.
Less undigested food reaching the colon
In principle, more complete breakdown of carbohydrate, protein and fat in the small intestine would leave less undigested food for colon bacteria to ferment into gas. This is a proposed mechanism; neither dyspepsia trial measured gas, fermentation or transit time.
Clinical trials
Randomized, double-blind, placebo-controlled, parallel trial of DigeZyme 50 mg three times daily for 60 days (Majeed et al. 2018, J Med Food). All authors were founders or employees of Sami Labs/Sabinsa, which makes and sells DigeZyme.
40 adults (20 per group) meeting Rome III criteria for functional dyspepsia at one hospital in Bangalore, India. Endoscopy to rule out reflux disease and other conditions was done in only 2 screened patients.
All five efficacy scales (SF-LDQ, NDI-SF, VAS, CGI-S, GDSS) improved more with DigeZyme than placebo (P values .0401 to .0033). Lower heartburn, epigastric pain, distention, indigestion and nausea item scores were reported within the DigeZyme group, not as between-group differences. No product-related adverse events. Small, maker-run and not yet repeated.
Single-center, randomized, double-blind, placebo-controlled trial of a multi-enzyme blend obtained from fungal fermentation, two 200 mg capsules a day (400 mg a day) for 2 months (Ullah et al. 2023, Biomed Pharmacother). The blend was not DigeZyme, and the authors declared no competing interests.
120 adults aged 18 to 59 (63 men, 57 women) with functional dyspepsia.
The enzyme group improved on the Nepean Dyspepsia Index short form (primary outcome, dyspepsia quality of life), pain severity on a visual analogue scale and sleep quality (PSQI), with no side effects reported. The authors concluded the blend reduced dyspepsia symptoms. No reflux-specific outcome was reported in the abstract.
Randomized, double-blind, placebo-controlled trial of a multi-enzyme complex identified as DigeZyme, 50 mg three times daily for 3 days (Vuppala et al. 2016, Sports Nutr Ther). Co-authored by M. Majeed and S. Majeed of Sami/Sabinsa, with capsules supplied by Sami Labs; the journal is not indexed in PubMed.
20 healthy men after a standardized eccentric exercise session.
At 72 hours, thigh pressure-pain (algometer) readings (p = 0.0436) and McGill pain questionnaire scores (p = 0.0061) favored the enzyme group. Calf pressure-pain, agility, muscle power and grip strength did not differ significantly, and creatine kinase (p = 0.57) and lactate dehydrogenase (p = 0.26) did not differ from placebo. No adverse events. Small, short and unreplicated.